Top Companies in the Patient-Derived Xenografts/PDX Models Market & Their Offerings
| Companies | Headquarters | Offerings |
| Charles River Laboratories | Massachusetts, USA | Large PDX tumor libraries, in vivo oncology testing, translational cancer research models, and drug efficacy evaluation services. |
| The Jackson Laboratory | Bar Harbor, Maine, USA | Provides mouse models, PDX systems, tumor biology research platforms, and precision oncology testing tools. |
| Crown Bioscience | California, USA | Delivers extensive PDX model platforms, immuno-oncology testing, biomarker research, and preclinical oncology services. |
| Altogen Labs | Texas, USA | Focuses on PDX model development, xenograft studies, and in vivo cancer drug testing for preclinical research. |
| Envigo (Inotiv) | Indiana, USA | Provides laboratory animal models, PDX and xenograft services, and toxicology and safety testing support. |
| WuXi AppTec | Shanghai, China | Offers integrated drug development services, including PDX models, oncology screening, and preclinical research support. |
| Oncodesign Services | Dijon, France | Specializes in PDX oncology models, translational pharmacology, and targeted cancer drug evaluation services |
What are the Recent Developments in the Patient-Derived Xenografts/PDX Models Market? 
- In May 2025, the NIH partnered with the FDA to reduce reliance on animal testing in funded research, encouraging the shift toward more human-relevant models. This move is expected to accelerate the adoption of advanced platforms like PDX alternatives in preclinical studies.
- In April 2025, the FDA announced a 3–5 year plan to gradually remove animal testing requirements for monoclonal antibody development. This shift increases the importance of PDX models and other advanced preclinical data as key supporting evidence in IND submissions.
Supply Chain Analysis
R&D:
- Patient-derived xenograft models support oncology research through tumor implantation, biomarker discovery, drug screening, genomic profiling, and translational studies. Advanced mouse models, AI analytics, and biobanking technologies improve reproducibility, precision, and preclinical validation efficiency.
- Companies: Champions Oncology, The Jackson Laboratory, Crown Bioscience, Charles River Laboratories, Hera BioLabs, Inotiv, Taconic Biosciences
Clinical Trials & Regulatory Approvals:
- PDX models accelerate clinical trial design by predicting therapeutic responses, validating biomarkers, and supporting precision medicine strategies. Regulatory agencies increasingly recognize translational evidence generated through PDX studies for oncology drug development submissions globally.
- Companies: Labcorp Drug Development, Eurofins Scientific, Pharmaron, WuXi AppTec, Covance, Crown Bioscience, Charles River Laboratories
Patient Support & Services:
- Patient support services in PDX workflows include tumor sample collection, biobanking, genomic analysis, personalized therapy recommendations, logistics coordination, and physician collaboration, ensuring efficient integration of precision oncology solutions into clinical practice.
- Companies: Xentech, Champions Oncology, Tempus, Caris Life Sciences, Precision for Medicine, LabConnect, ICON plc
Market Growth
The global patient-derived xenografts/PDX models market size was estimated at USD 612.4 million in 2025 and is predicted to increase from USD 696.91 million in 2026 to approximately USD 2230.79 million by 2035, expanding at a CAGR of 13.8% from 2026 to 2035.
Keypoints
- Company Overview
- Locations Subsidiaries/Geographic reach
- Key Executives
- Company Financials
- Patents registered
- SWOT Analysis
- Applications Catered
- Strategic collaborations
- Recent Developments
- Competitive Benchmarking